Todas las investigaciones
ReclutamientoConfirmatorio terapéutico (Fase III)Intervencionista

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (LIBerate-OLE)

This study is a long-term follow-up for people who have taken part in earlier trials for a drug called Lerodalcibep (LIB003). It's for individuals with very high cholesterol, often due to a family history, heart disease, or a high risk of developing it. The main goal is to see if Lerodalcibep continues to be effective at lowering 'bad' cholesterol (LDL-C) over a longer period, specifically 48 and 72 weeks. Researchers will also be checking its safety and how the drug affects other fats in the blood. This helps them understand the consistent benefits and any long-term effects of the medication when added to their usual cholesterol-lowering treatments.

De un vistazo

Estado
Reclutamiento
Fase
Confirmatorio terapéutico (Fase III)
Patrocinador
Lib Therapeutics LLC
Objetivo de inscripción
590
Inicio
11 Apr 2024

¿De qué trata este estudio?

This study is about a new medication called Lerodalcibep (also known as LIB003). It's designed for people who have very high cholesterol that can be difficult to manage with standard medications alone. This can include individuals with an inherited condition causing high cholesterol (called familial hypercholesterolemia), those who already have heart disease, or people at a high risk of developing heart disease in the future.

The main purpose of this particular study is to continue observing people who have already taken Lerodalcibep in earlier research studies. It's like checking in on how a new treatment works over a longer time. Researchers want to understand if Lerodalcibep keeps lowering 'bad' cholesterol (LDL-C) effectively for up to 72 weeks, and they will also carefully monitor any side effects to make sure it remains safe. They'll also look at how the drug affects other types of fats in your blood.

By taking part, you would be helping doctors and researchers understand the long-term benefits and safety of Lerodalcibep. This information is crucial for deciding if this medication could become a widely available treatment for people struggling with very high cholesterol, helping them reduce their risk of heart problems.

Puntos clave

  • This study is for people already in a Lerodalcibep (LIB003) cholesterol trial.
  • It aims to check the long-term effectiveness and safety of Lerodalcibep.
  • It focuses on lowering 'bad' cholesterol (LDL-C) in people with severe high cholesterol.
  • Participants must be on stable cholesterol-lowering medicines already.
  • The study lasts up to 72 weeks and involves regular health checks.

¿Quién puede ser elegible?

This study is open to adults aged 18 and over. It's specifically for people who have already participated in other Lerodalcibep studies (LIB003-003, LIB003-004, LIB003-005, LIB003-006, LIB003-008, LIB003-011, or LIB003-012).

You would be eligible if you have very high cholesterol, either due to a family history (familial hypercholesterolemia), or if you already have heart and blood vessel disease. You might also be considered if you are at a high risk of developing heart disease.

Crucially, you must already be on a stable dose of other cholesterol-lowering medicines, meaning your current treatment isn’t bringing your cholesterol down enough on its own.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Have you previously participated in a Lerodalcibep (LIB003) study?
  3. Do you have very high cholesterol, maybe due to family history or heart disease?
  4. Are you currently taking other cholesterol-lowering medications at a steady dose?
  5. Do you need further reduction in your 'bad' cholesterol levels?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you take part in this study, you would continue to receive the study drug, Lerodalcibep. The study will involve regular visits to the clinic over a period of up to 72 weeks (about 1.5 years). During these visits, doctors will take blood samples to measure your cholesterol levels and other blood fats, and they will also check for any antibodies against the drug.

You will have physical examinations, electrocardiograms (ECGs) to check your heart, and your vital signs (like blood pressure and pulse) will be monitored. Researchers will also ask about any changes in your health or any side effects you might experience. The aim is to carefully track how the drug affects your body over time.

Riesgos y beneficios potenciales

Taking part could offer the benefit of continuing to receive a medication that may effectively lower your 'bad' cholesterol, potentially reducing your risk of heart problems. However, as with any medication, there's always a possibility of side effects. The study will closely monitor for any adverse effects, including heart-related events or issues with your liver or muscles. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Ubicaciones (4)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    España
  • —
    No verificado
    Alemania
  • —
    No verificado
    Francia
  • —
    No verificado
    Noruega

Preguntas comunes

What is 'bad' cholesterol (LDL-C)?

LDL-C is a type of cholesterol that can build up in your arteries, making them narrower and increasing your risk of heart disease. Lowering it is often a key goal in heart health.

What is familial hypercholesterolemia?

This is an inherited condition where your body can't remove 'bad' cholesterol from your blood properly, leading to very high cholesterol levels from a young age.

What does 'on stable lipid-lowering therapy' mean?

It means you are already taking other medicines to lower your cholesterol (like statins), and you've been on a consistent dose of these for a while.

How long will I be in this study?

This study can last up to 72 weeks, which is about 1.5 years, with regular check-ups during that time.

What if I experience side effects?

Any side effects or changes in your health will be carefully monitored by the study team during your visits, and you should report any concerns you have.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Open-Label Extension Phase 3 Study to Evaluate the Long-Term…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.